Download PDF
CC BY-NC-ND 4.0 · Journal of Health and Allied Sciences NU 2022; 12(01): 96-97
DOI: 10.1055/s-0041-1731915
Case Report

A Relapsing Immune Thrombocytopenia Case in a Patient Following COVID-19 Vaccination

Burcin Meryem Atak Tel 
1   Department of Internal Medicine, Abant Izzet Baysal University Hospital, Bolu, Turkey
,
Gizem Kahveci 
1   Department of Internal Medicine, Abant Izzet Baysal University Hospital, Bolu, Turkey
,
Tuba Taslamacioglu Duman 
1   Department of Internal Medicine, Abant Izzet Baysal University Hospital, Bolu, Turkey
,
Özge Kurtkulagi 
1   Department of Internal Medicine, Abant Izzet Baysal University Hospital, Bolu, Turkey
,
Satilmis Bilgin 
1   Department of Internal Medicine, Abant Izzet Baysal University Hospital, Bolu, Turkey
,
Hilal Senturk 
1   Department of Internal Medicine, Abant Izzet Baysal University Hospital, Bolu, Turkey
,
Havva Akin 
1   Department of Internal Medicine, Abant Izzet Baysal University Hospital, Bolu, Turkey
,
Gulali Aktas 
1   Department of Internal Medicine, Abant Izzet Baysal University Hospital, Bolu, Turkey
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

There are several vaccines developed against COVID-19 infection. Inactivated viral vaccines are usually well tolerated. We aimed to present a relapsing immune thrombocytopenia case following inactive COVID-19 vaccine. Here we report a case of relapsing immune thrombocytopenia following inactivated viral vaccine against COVID-19 in a 60-year-old woman with a history of immune thrombocytopenia. The patient responded well to dexamethasone treatment and was discharged from the hospital with full recovery. We suggest that physicians seek the history of a recent inactivate COVID-19 vaccine shot in patients with immune thrombocytopenia.

Keywords

COVID-19 - immune thrombocytopenia - inactivated viral vaccine


Publication History

Article published online:
23 July 2021

© 2021. Nitte (Deemed to be University). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Flaxman S, Mishra S, Gandy A. et al Imperial College COVID-19 Response Team. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020; 584 (7820) 257-261
    CrossrefPubMedGoogle Scholar
  • 2 Aktas G, Altinordu R, Mercan Z, Savli H. Immune thrombocytopenia; following seasonal flu vaccine and nonsteroidal anti-inflamatory drug use. Prof Med J 2016; 23: 630-633
    Google Scholar
  • 3 Woods Jr VL, Oh EH, Mason D, McMillan R. Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP. Blood 1984; 63 (02) 368-375
    CrossrefPubMedGoogle Scholar
  • 4 Fogarty P, Minichiello T. Disorders of hemostasis, thrombosis, and antithrombotic therapy. In: Papadakis MA, McPhee SJ, eds. Current Medical Diagnosis and Treatment. 54th ed. New York, NY: McGraw Hill Lange Publication 2015: 536-561
  • 5 Peltola H, Heinonen OP, Valle M. et al The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994; 331 (21) 1397-1402
    CrossrefPubMedGoogle Scholar
  • 6 Meyboom RH, Fucik H, Edwards IR. Thrombocytopenia reported in association with hepatitis B and A vaccines. Lancet 1995; 345 (8965) 1638
    CrossrefPubMedGoogle Scholar
  • 7 Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005; 23 (30) 3876-3886
    CrossrefPubMedGoogle Scholar